Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches.

Slides:

Advertisements

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Advertisements

10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.

Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.

Weight Management Overweight and Underweight Copyright 2005 Wadsworth Group, a division of Thomson Learning.

Beyond Dieting: New Weight Loss Medications & Treatments on the Horizon Daniel Bessesen, MD.

1 Future Areas of Research Intervention Approaches Causes and Mechanisms of Overweight and Obesity Abdominal Fat, Body Weight and Disease Risk Assessment.

THE PHARMACOLOGY OF OBESITY DR. HANIN OSAMA. DEFINITION OF OBESITY BMI (Grade 1, overweight) BMI (Grade 2, obese) BMI > 40 (Grade 3, Morbidly.

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 82 Drugs for Weight Loss.

VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.

ANTI OBESITY PRESCRIBING 19 th November 2013 V.Welch.

Bariatric Surgery and Metabolism Goal: to review 4 important and clinically relevant papers from 2010 on Bariatric Surgery and Metabolism 10/10/20151.

Obesity Case Study. What is your history with weight gain and weight loss? Would you like to manage your weight differently? If so, how? What do you think.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Body weight and composition Thursday: Exam #1 Bring: Pencil Pen Green Scantron form.

 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.

Management of Obesity in Diabetes Key Messages An estimated 80 to 90% of persons with type 2 diabetes are overweight or obese. A modest weight loss of.

Drugs for Weight Loss 1.

Body weight and composition

Overweight and Obesity: Validation as a Chronic Disease

Deciphering Obesity Management Guidelines

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

Weight Regulation: Discovery Timeline

The role of metabolic surgery in the management of obesity and t2dm

The "Metabolically Healthy Obese"

Updates on Emerging GLP-1 Receptor Agonists

Does One Size Fit All in Obesity Management?

Updates on Obesity Treatment:

Patient Outcomes in Bariatric Surgery: Bridging the Divide to Postoperative Success.

SGLT2 Inhibitors in Phase 3 Trials

Through Thick and Thin.

Can Primary Care Physicians Take the Lead in Combating Obesity?

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Obesity Management Today:

Selecting NOACs for High-Risk Patients

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Metabolically Healthy Patients With Obesity

Precision Management of RA and Comorbidities

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Evaluating Next-Generation BTK Inhibitors

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Clinicians' Corner in Dyslipidemia

Better Diabetes Control With Novel Basal Insulins

Practical Challenges in Obesity: Is It Possible to Maintain Weight Loss?

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Dual SGLT1/SGLT2 Inhibition in T1D

THE TRUTH ABOUT MODERN OBESITY AGENTS: ARE THEY REALLY SAFE AND EFFECTIVE?

Obesity and Weight Loss: How Can Cross-Functional Collaboration and Integrated Care Work in Practice?

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

Treating Obesity as a Disease: What Are the Underlying Causes?

Maximizing Organ Protection in Patients With CKD and Comorbidities on RAAS Therapy.

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Obesity Management.

Section overview: Cardiometabolic risk reduction

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

NAFLD and NASH in Europe and Canada

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Embracing Obesity in Collaboration -- Why, When, and How to Intervene

Presentation transcript:

Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches

Mean BMI Around the Globe in Men 18 and Over: 2014

The Risk for Comorbid Disease With Increasing BMI

Weight Loss, Metabolic, and Other Health Benefits

Mechanisms Involved in the Development of T2DM

The Link Between the Gut, Brain, Adipose Tissue, and Body Weight

Interventions for Weight Loss in the Overweight and Obese

Barriers and Complications to Obesity Management

EMA Approved Treatments for Weight Management Prior to 2015

Orlistat Reversibly Inhibits Lipases in the GI Tract

XENDOS: Effect of Long-term Treatment With Orlistat on Body Weight

Mean Changes in Coronary Heart Disease Risk Factors With Orlistat

Reported Adverse Effects With Orlistat Use

Naltrexone SR /Bupropion SR MOA to Initiate and Sustain Weight Loss

Effect of Naltrexone SR/Bupropion SR on Body Weight Across Multiple Trials

Naltrexone SR/Bupropion SR: Most Common Treatment-Emergent AEs

GLP-1 Secretion in the Gut and Appetite Regulation

Liraglutide Approval for Weight Management

SCALE Obesity and Prediabetes: Effect of Liraglutide on Weight at 56 Weeks

Liraglutide: TEAEs Reported in Phase 3 Trials

Liraglutide vs Orlistat For Weight Loss in Patients Without Diabetes Who Are Obese

Guidelines Recommendations for the Management of Obese Patients

Practical Weight-loss Objectives in Patients With Obesity

Abbreviations

Abbreviations (cont)

Abbreviations (cont)